Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study

Abstract Background Over the past decades, remarkable advancements in systemic drug therapy have improved the prognosis of patients with bone metastases. Individualization is required in external beam radiotherapy (EBRT) for bone metastases according to the patient’s prognosis. To establish individu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, Masaaki Kataoka, Shuhei Yamamoto, Kei Nagasaki, Hirofumi Ishikawa, Noriko Takata, Shintaro Tsuruoka, Kotaro Uwatsu, Teruhito Kido
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Bone metastases Local control External beam radiotherapy Prognostic factor Individualized radiotherapy Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/42a7ab88a15f4140a8962089e2e820f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:42a7ab88a15f4140a8962089e2e820f4
record_format	dspace
spelling	oai:doaj.org-article:42a7ab88a15f4140a8962089e2e820f42021-11-21T12:14:09ZLocal control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study10.1186/s13014-021-01940-01748-717Xhttps://doaj.org/article/42a7ab88a15f4140a8962089e2e820f42021-11-01T00:00:00Zhttps://doi.org/10.1186/s13014-021-01940-0https://doaj.org/toc/1748-717XAbstract Background Over the past decades, remarkable advancements in systemic drug therapy have improved the prognosis of patients with bone metastases. Individualization is required in external beam radiotherapy (EBRT) for bone metastases according to the patient’s prognosis. To establish individualized EBRT for bone metastases, we investigated factors that affect the local control (LC) of bone metastases. Methods Between January 2010 and December 2019, 536 patients received EBRT for 751 predominantly osteolytic bone metastases. LC at EBRT sites was evaluated with a follow-up computed tomography. The median EBRT dose was biologically effective dose (BED10) (39.0) (range of BED10: 14.4–71.7 Gy). Results The median follow-up time and median time of computed tomography follow-up were 11 (range 1–123) months and 6 (range 1–119) months, respectively. The 0.5- and 1-year overall survival rates were 73% and 54%, respectively. The 0.5- and 1-year LC rates were 83% and 79%, respectively. In multivariate analysis, higher age (≥ 70 years), non-vertebral bone metastases, unfavorable primary tumor sites (esophageal cancer, colorectal cancer, hepatobiliary/pancreatic cancer, renal/ureter cancer, sarcoma, melanoma, and mesothelioma), lower EBRT dose (BED10 < 39.0 Gy), and non-administration of bone-modifying agents (BMAs)/antineoplastic agents after EBRT were significantly unfavorable factors for LC of bone metastases. There was no statistically significant difference in the LC between BED10 = 39.0 and BED10 > 39.0 Gy. Conclusions Regarding tumor-related factors, primary tumor sites and the sites of bone metastases were significant for the LC. As for treatment-related factors, lower EBRT doses (BED10 < 39.0 Gy) and non-administration of BMAs/antineoplastic agents after EBRT were associated with poor LC. Dose escalation from BED10 = 39.0 Gy did not necessarily improve LC.Kenji MakitaYasushi HamamotoHiromitsu KanzakiMasaaki KataokaShuhei YamamotoKei NagasakiHirofumi IshikawaNoriko TakataShintaro TsuruokaKotaro UwatsuTeruhito KidoBMCarticleBone metastasesLocal controlExternal beam radiotherapyPrognostic factorIndividualized radiotherapyMedical physics. Medical radiology. Nuclear medicineR895-920Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENRadiation Oncology, Vol 16, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Bone metastases Local control External beam radiotherapy Prognostic factor Individualized radiotherapy Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Bone metastases Local control External beam radiotherapy Prognostic factor Individualized radiotherapy Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kenji Makita Yasushi Hamamoto Hiromitsu Kanzaki Masaaki Kataoka Shuhei Yamamoto Kei Nagasaki Hirofumi Ishikawa Noriko Takata Shintaro Tsuruoka Kotaro Uwatsu Teruhito Kido Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
description	Abstract Background Over the past decades, remarkable advancements in systemic drug therapy have improved the prognosis of patients with bone metastases. Individualization is required in external beam radiotherapy (EBRT) for bone metastases according to the patient’s prognosis. To establish individualized EBRT for bone metastases, we investigated factors that affect the local control (LC) of bone metastases. Methods Between January 2010 and December 2019, 536 patients received EBRT for 751 predominantly osteolytic bone metastases. LC at EBRT sites was evaluated with a follow-up computed tomography. The median EBRT dose was biologically effective dose (BED10) (39.0) (range of BED10: 14.4–71.7 Gy). Results The median follow-up time and median time of computed tomography follow-up were 11 (range 1–123) months and 6 (range 1–119) months, respectively. The 0.5- and 1-year overall survival rates were 73% and 54%, respectively. The 0.5- and 1-year LC rates were 83% and 79%, respectively. In multivariate analysis, higher age (≥ 70 years), non-vertebral bone metastases, unfavorable primary tumor sites (esophageal cancer, colorectal cancer, hepatobiliary/pancreatic cancer, renal/ureter cancer, sarcoma, melanoma, and mesothelioma), lower EBRT dose (BED10 < 39.0 Gy), and non-administration of bone-modifying agents (BMAs)/antineoplastic agents after EBRT were significantly unfavorable factors for LC of bone metastases. There was no statistically significant difference in the LC between BED10 = 39.0 and BED10 > 39.0 Gy. Conclusions Regarding tumor-related factors, primary tumor sites and the sites of bone metastases were significant for the LC. As for treatment-related factors, lower EBRT doses (BED10 < 39.0 Gy) and non-administration of BMAs/antineoplastic agents after EBRT were associated with poor LC. Dose escalation from BED10 = 39.0 Gy did not necessarily improve LC.
format	article
author	Kenji Makita Yasushi Hamamoto Hiromitsu Kanzaki Masaaki Kataoka Shuhei Yamamoto Kei Nagasaki Hirofumi Ishikawa Noriko Takata Shintaro Tsuruoka Kotaro Uwatsu Teruhito Kido
author_facet	Kenji Makita Yasushi Hamamoto Hiromitsu Kanzaki Masaaki Kataoka Shuhei Yamamoto Kei Nagasaki Hirofumi Ishikawa Noriko Takata Shintaro Tsuruoka Kotaro Uwatsu Teruhito Kido
author_sort	Kenji Makita
title	Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
title_short	Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
title_full	Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
title_fullStr	Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
title_full_unstemmed	Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
title_sort	local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/42a7ab88a15f4140a8962089e2e820f4
work_keys_str_mv	AT kenjimakita localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT yasushihamamoto localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT hiromitsukanzaki localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT masaakikataoka localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT shuheiyamamoto localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT keinagasaki localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT hirofumiishikawa localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT norikotakata localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT shintarotsuruoka localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT kotarouwatsu localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy AT teruhitokido localcontrolofbonemetastasestreatedwithexternalbeamradiotherapyinrecentyearsamulticenterretrospectivestudy
_version_	1718419117836337152

Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study

Ejemplares similares